EP3814326A4 - Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases - Google Patents

Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases Download PDF

Info

Publication number
EP3814326A4
EP3814326A4 EP19825897.2A EP19825897A EP3814326A4 EP 3814326 A4 EP3814326 A4 EP 3814326A4 EP 19825897 A EP19825897 A EP 19825897A EP 3814326 A4 EP3814326 A4 EP 3814326A4
Authority
EP
European Patent Office
Prior art keywords
hbv
treatment
induced diseases
dihydropyrimidine derivatives
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19825897.2A
Other languages
German (de)
French (fr)
Other versions
EP3814326A1 (en
Inventor
Gang Deng
Yimin Jiang
Qian Liu
Chao Liang
Zhao-Kui Wan
Wing Shun CHEUNG
Zhanling CHENG
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of EP3814326A1 publication Critical patent/EP3814326A1/en
Publication of EP3814326A4 publication Critical patent/EP3814326A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19825897.2A 2018-06-26 2019-06-25 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases Withdrawn EP3814326A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018092875 2018-06-26
US201862716823P 2018-08-09 2018-08-09
PCT/CN2019/092857 WO2020001448A1 (en) 2018-06-26 2019-06-25 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Publications (2)

Publication Number Publication Date
EP3814326A1 EP3814326A1 (en) 2021-05-05
EP3814326A4 true EP3814326A4 (en) 2022-03-16

Family

ID=68984711

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19825897.2A Withdrawn EP3814326A4 (en) 2018-06-26 2019-06-25 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Country Status (8)

Country Link
EP (1) EP3814326A4 (en)
JP (1) JP2021529188A (en)
KR (1) KR20210025596A (en)
CN (1) CN112513017A (en)
AU (1) AU2019296117A1 (en)
CA (1) CA3099605A1 (en)
MA (1) MA53023A (en)
WO (1) WO2020001448A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
US11053235B2 (en) * 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
CN114989097A (en) * 2022-05-20 2022-09-02 无锡捷化医药科技有限公司 Preparation method of 5-amino-6-chloropyrimidine-4-carboxylic acid ethyl ester

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179131B2 (en) * 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3645516A4 (en) * 2017-06-27 2021-07-07 Janssen Pharmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals

Also Published As

Publication number Publication date
CN112513017A (en) 2021-03-16
MA53023A (en) 2021-05-05
CA3099605A1 (en) 2020-01-02
KR20210025596A (en) 2021-03-09
EP3814326A1 (en) 2021-05-05
AU2019296117A1 (en) 2020-11-26
WO2020001448A1 (en) 2020-01-02
JP2021529188A (en) 2021-10-28

Similar Documents

Publication Publication Date Title
IL246564A (en) 3-aryl-1-heterocyclyl-pyrazolo[3,4-d]pyrimidine derivatives and use thereof in the treatment of diseases
IL286210A (en) Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
PL3759083T3 (en) 2,4-diaminoquinazoline derivatives and use thereof in the treatment of virus infections, cancer or allergies
EP3814326A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP3790866A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP3344632A4 (en) Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
EP3632440A4 (en) Use of ligustrazine nitrone derivatives in prevention and treatment of diabetic complication diseases
SG11202004408YA (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
EP3969125A4 (en) Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
EP3488850A4 (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
EP3600305A4 (en) Berberine alkaloid formulations in the prevention and/or treatment of infectious disease
EP4003355A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP3632433A4 (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
EP4003997A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
IL272495A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
EP3687629A4 (en) Treatment and detection of infection and disease associated with different fungal pathogens
EP4003987A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
TWI799923B (en) Use of thioimidazolidinone drugs in the treatment of covid-19 disease
EP3458058A4 (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
PL3937949T3 (en) Phytoecdysones and the derivatives thereof for use in the treatment of impaired lung function
EP3749332A4 (en) Compositions and their use in the treatment of endometriosis and pain
EP3474840A4 (en) Use of cyanoglucosides and pharmaceutical formulations thereof in the treatment of diabetes
PL3813843T3 (en) Composition for use in the prevention and/or treatment of osteoarticular diseases
EP3389649A4 (en) Compound for use in the treatment and/or prevention of parasitic mediated diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0239220000

Ipc: C07D0417140000

A4 Supplementary search report drawn up and despatched

Effective date: 20220216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/20 20060101ALI20220210BHEP

Ipc: A61K 31/506 20060101ALI20220210BHEP

Ipc: C07D 417/14 20060101AFI20220210BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230425